No Data
No Data
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Rodman & Renshaw analyst Anthony Butler initiates coverage on $Nektar Therapeutics(NKTR.US)$ with a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success ra
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Oppenheimer analyst Jay Olson maintains $Nektar Therapeutics(NKTR.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 43.6% and a total average return of 16.3% over t
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
$Nektar Therapeutics(NKTR.US)$ Director CHESS ROBERT sold 19,500 shares of common stock on Jun 14, 2024 at an average price of $1.2 for a total value of $23,400.Source: Announcement What is statement
Express News | Nektar Therapeutics - Ind-Enabling Studies Underway for Nktr-0165 With First-in-Human Studies Planned in First Half of 2025
Express News | Nektar Therapeutics: Nktr-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism
Express News | Nektar Therapeutics Presents First Preclinical Data on Nktr-0165, a Tnfr2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at Eular 2024